Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2014. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMR), or connected persons, specifically regarding the vesting of conditional share awards under the GlaxoSmithKline Share Value Plan (SVP).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to the fair market value of shares at the time of vesting:
- Ordinary Share fair market value: £16.83
- American Depositary Share (ADS) fair market value: US$55.75
Material Changes
The material event reported is the conclusion of the three-year vesting period for 2011 SVP awards, which commenced on February 24, 2011, and ended on February 24, 2014. The filing details the specific number of shares vested for connected persons:
| Director / PDMR | Connected Person | Ordinary Shares Vested | ADS Vested |
|---|---|---|---|
| Mr P Thomson | Mrs K Thomson | 2,210 | 0 |
| Dr M Slaoui (Executive Director) | Mrs K Slaoui | 0 | 2,450 |
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or discussion of contingencies. It is strictly a regulatory disclosure of equity transactions in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).
Key Facts for Investor Verification
- Verify the total number of shares vested for executive directors and their connected persons as of February 24, 2014.
- Confirm the share price used for valuation (£16.83 for Ordinary Shares and US$55.75 for ADS) matches market data for February 24, 2014.
- Note that this filing does not contain operational or financial results for the company.